“We have decided to invest in genXone S.A. because this entity operates in a very promising and important industry, i.e. biotechnology. This company has great scientific and organizational potential to carry out research on the characteristics of the SARS-CoV-2 coronavirus, and their results may contribute to accelerating the work on a vaccine and a drug for COVID-19. In turn, the Molecular Diagnostics Laboratory belonging to genXone S.A. was put by the Ministry of Health on the list of regional laboratories performing tests for SARS CoV-2 virus, thanks to which the company has the opportunity to support the public health service in the field of diagnostic tests for SARS CoV-2 financed by the National Health Fund” emphasizes January Ciszewski, President of the Management Board JR HOLDING ASI SA.